# Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)

> **NCT02430714** · — · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 629 (actual)

## Conditions studied

- Thyroid Neoplasms

## Interventions

- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT02430714
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-20
- **Primary completion:** 2016-11-06
- **Final completion:** 2016-11-06
- **Target enrollment:** 629 (ACTUAL)
- **Last updated:** 2020-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02430714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02430714, "Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02430714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*